• Increase font size
  • Default font size
  • Decrease font size
home | about us | contact us
Search
Search Only:

Search Keyword extreme trade

Total: 50 results found.

... Inc., and CallForceOne Consulting Group. Gierhart commented, "Betsy understands the needs of our customers extremely well and we're excited to expand her responsibilities within the ZeaVision business." ...
...  “At Saint Barnabas Medical Center, we see over 84,000 emergency department patients each year. The AutoPulse is extremely useful in Code Blue situations since it is easy to apply and fit to the patient. ...
... clinicians to constantly log-on to and off of shared workstations.And privacy regulations are extremely strict," said David Ting, founder and CTO of Imprivata."Our combined solution allows clinicians to ...
... will be a valuable asset for the growth and the promotion of the Gummy Bear. The domestic nutrition product market for children is extremely large and we believe that the cooperation with Nepstar will ...
... of Pluristem’s PLX cells may prevent or delay the development of this extremely common but devastating disease. "There has been a growing interest in the potential of PLX cells to treat a variety of ...
... commence enrollment. "We are extremely pleased with the outcome of these meetings. We recognize the care and prudence ...
... our new report. While there are some success stories in the industry, a number of players are having trouble dealing with the volatile nature of biotechnologies. Research and development costs are extremely ...
... being down at these levels. We think of it this way: Even if ILNS were played this as one of our FDA extreme trades, given the number of expected catalysts and news from the numerous Phase I, II and ...
... customers. "Optimizing integrity throughout the entire sample life cycle has taken on extreme scientific and financial ...
... from patients and physicians regarding Kuvan's impact beyond blood Phe level reduction, BioMarin has never formally evaluated these endpoints in a company trial due to the extremely short development time ...
... of complete Miltenyi Biotec systems, including the autoMACS(R) Pro Separator, the gentleMACS(TM) Dissociator and the MACSQuant(R) Analyzer. "We are extremely pleased to be working together with Miltenyi ...
... consumer brands. Peter Cunningham, Gamma's Chief Executive Officer, commented on the news, "We are extremely excited about this important milestone.Over the last two years, Gamma has finalized our product ...
... compounded IVs are the last gap in the pharmacy automation process,” said Stanton McComb, president, McKesson Automation. “We are extremely pleased to have been selected by UMass Memorial Medical ...
... in a uniquely powerful way.  We believe that West Coast investors will be extremely interested to hear about our innovative HIV vaccine program and how we intend to maximize its market potential within ...
... mice and dogs have been studied. "ABX-CRO is extremely pleased that ANAVEX has chosen us as partner to conduct ...
16. Catalyst financing looks favorable
(Home Page/Home Page)
... lifted.   On the heels of this news and based on the fact that the CPRX chart looks extremely bullish, Goldman Small Cap Research believes that investing in Catalyst at current levels is a ...
... including: new or worse aggressive behavior, hostility, anger or irritability new or worse bipolar illness or mania (an extreme increase in activity or talking) new or worse psychosis (hearing ...
... behavior, hostility, anger or irritability new or worse bipolar illness or mania (an extreme increase in activity or talking) new or worse psychosis (hearing or seeing things that are not real, being ...
... INC. (OTC Bulletin Board: OXIS, Paris: OXI) is extremely proud to announce the appointment of Dr. John Repine to the OXIS International Scientific Advisory Board. Phase Forward Incorporated (NASDAQ: ...
... saw strong growth, particularly in reagent test revenues. In addition, placements of our XT-8 system exceeded our expectations and we are extremely pleased with the productivity of our new and still ...
...  stated, “We are extremely pleased with the performance of XIFAXAN550 and anticipate ongoing revenue growth as XIFAXAN550 continues to gain traction and build momentum in the hepatic encephalopathy ...
...  "At quarter end, our leverage ratio was just 1.6x Adjusted EBITDA, and we were upgraded by both Moody's and the S&P," Bisaro added.  "I am extremely ...
... fiscal 2011 to a range of $2.38 to $2.48 from its preliminary outlook of $2.35 to $2.45. "I am extremely proud ...
...  "We are extremely pleased with Medifast's strong second quarter revenue and earnings performance.  Our multi-platform ...
... XE6 or Cray XT6 systems do not perform as expected or as required by customers, the risk that we are unable to successfully manufacture what for us would be an extremely large number of system cabinets ...
... is extremely unique and it delivers drugs comfortably through the skin using low-level electrical energy. This active patch technology allows precise dosing, giving physicians and patients ...
27. Unexpected Comeback With Clinical Data and Pending Deal
(Premium Content/Subscriber Only Content)
... (iontophoresis) is extremely unique and it delivers drugs comfortably through the skin using low-level electrical energy. This active patch technology allows precise dosing, giving physicians ...
... from therapy. In many, but not all cases, these disorders resolve after stopping PEGINTRON therapy.   Use with Ribavirin: Ribavirin may cause birth defects and death of the unborn child. Extreme ...
... Xibrom and Vitrase revenues.  While overall prescription trends for all products have been extremely strong, there has been a trend with wholesalers to hold less inventory, especially as they approached ...
LAKE FOREST, Ill.--(BUSINESS WIRE)--Akorn, Inc. (NASDAQ:AKRX), a niche generic pharmaceutical company, today reported financial results for the second quarter ended June 30, 2010. “Ware extremely ...
...  "We are extremely pleased with the rapid progress being made towards completion of this confirmatory safety and efficacy study," said ...
... risk is established.” “There was a 38 percent increase in nominations this year and the judges found selecting only 50 finalists to be extremely challenging,” explained Audrey Russo, President ...
... Communications and Gaiam to Release Extreme Survival Pack, Clash of the Dinosaurs, and Showdown Air Combat on DVD this August Speedway SuperAmerica Announces Speedy ...
... News Releases in Earnings Forecasts & Projections Comstock Resources, Inc. Reports Second Quarter 2010 Financial and Operating Results Extreme ...
... image and profile extreme features such as these, is generating interest from a wide array of biotechnology providers.” Zeta Instruments systems are unique in offering multi-function metrology features ...
... military and international standards related to durability, environmental operation and storage extremes, radio frequency emissions, and susceptibility to spurious electrical and radio frequency noise. ...
... President of Hop-on, "This is the only product of its kind on Amazon.com to date. We are extremely excited about the exposure and potential sales the companies will generate from this patch and future ...
... from 0 (no symptoms) to 40 (very severe symptoms) and the CGI-1 from 1 (not ill at all) to 7 (extremely ill). Secondary efficacy variables included the proportion of treatment responders for IRLS and CGI-1. ...
... can be used for a wide range of clinical research applications. The API 4000 quantifies the amount of drugs in saliva at extremely low levels of detection, which are not possible to detect with alternative ...
... So it’s extremely conservative. $70 million the first year and by the third year where we would peak out at about 1.5% penetration, we believe they have a product doing in excess of $200 million in the ...
... as a generics manufacturer and supplier. “Since we launched our own label only three years ago, Amneal is extremely honored to receive industry-wide recognition by these top wholesalers-distributors” ...
...  cases, these disorders resolve after stopping PEGINTRON therapy.   Use with Ribavirin: Ribavirin may cause birth defects and death of the unborn child. Extreme care must be taken to avoid ...
... industry is extremely trade-oriented with over 90 percent of domestic demand for medical devices being satisfied through imports and export of over 90 percent of products manufactured in Australia. Many ...
...  leverage that we have created through our manufacturing rationalization programs is delivering strong improvements in profitability. I am extremely proud of the achievements of Ferro ...
... by Sanofi-Aventis. "The approval of M-Enoxaparin marks a key milestone for Momenta, and we are extremely pleased," commented Craig Wheeler, President and CEO. "This is the first product based on Momenta's ...
...  translated promising science into novel therapeutics. Bob’s contributions to the Board will be extremely valuable as Anchor advances its projects toward clinical stage development.” Dr. Kamen ...
47. Small Biotech Breaking Down Barriers in Autism Research
(BioMedReports.com Articles/User Submitted Articles)
... ago, its diagnosis rate has escalated dramatically recently to 1 out of every 110 births. It will affect more children this year than AIDS, cancer and diabetes combined. It is an area that has an extremely ...
... enable the simultaneous performance of thousands of sophisticated biochemical measurements in extremely minute volumes. These “integrated circuits for biology” are made possible by miniaturizing ...
... secured to the skull and removed between treatments.   "We were extremely encouraged to find a non-invasive treatment that ...
... to tumor ablation with PV-10. We believe the clarity that this study will provide will be extremely helpful, and could be used to petition the FDA for accelerated approval of PV-10. We also expect ...

Get Free Email and Phone News Alerts

* Your email address:
* Preferred Format:
* Enter the security code shown:
 
Home | Privacy Policy
© 2010 BioMedReports.com. All rights reserved